Elpiscience Biopharma, Ltd.
6 clinical trials · Sponsor
◉ Watch Elpiscience Biopharma, Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05381935) | Elpiscience Biopharma, Ltd. | 2023-04-21 |
| A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05075564) | Elpiscience Biopharma, Ltd. | 2021-12-23 |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (NCT04991506) | Elpiscience Biopharma, Ltd. | 2021-10-15 |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors (NCT04841538) | Elpiscience Biopharma, Ltd. | 2021-07-01 |
| A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (NCT04730843) | Elpiscience Biopharma, Ltd. | 2021-04-01 |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors (NCT04009460) | Elpiscience Biopharma, Ltd. | 2019-06-28 |
Track Elpiscience Biopharma, Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.